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Abstract—Rapid changes in the light–dark cycle cause circadian desynchronization between rhythms of spike–wave dis-
charges (SWDs) and motor activity in genetic epileptic rats, and this is accompanied by an increase in epileptic activity.
Given the close relationship between absence seizures and sleep–wake states, the present study assessed ﬁrstly a puta-
tive relationship between vigilance rhythms and SWDs during re-synchronization, and secondly sleep–wake patterns
responsible for increased epileptic activity. Lastly, in a view of existing evidence that melatonin and its agonists acceler-
ate re-synchronization, the effects of different doses of agomelatine upon the speed of re-synchronization of different
sleep–wake states and SWDs were investigated.Simultaneous electroencephalographic and electromyographic record-
ings were made in symptomatic WAG/Rij rats, before, during and 10 days following an 8 h light phase delay. Agomelatine
was orally administered acutely and sub-chronically, during 10 post-shift days.The magnitude of the advance after the
shift and the speed of re-synchronization were speciﬁc for various rhythms. Most prominent change was the increase
in REM sleep duration during the dark phase. A post-shift increase in passive wakefulness and a reduction in deep
slow-wave sleep coincided with an aggravation of SWDs during the light phase. Agomelatine showed neither an effect
on sleep–wake parameters and SWDs, nor affected re-synchronization.The same speed of re-synchronization of SWDs
and light slow-wave sleep suggests that both are controlled by a common circadian mechanism. The redistribution of
SWDs and their increase in the light phase after the shift may be of importance for patients with absence epilepsy plan-
ning long trans-meridian ﬂight across time zones. © 2019 IBRO. Published by Elsevier Ltd. All rights reserved.
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INTRODUCTION
Survival of the organism, successful adaptation to a particular
ecological niche, and well-being of the organism are all
ensured by a proper synchronization of the circadian timing
system to the environmental cycles (Dodd et al., 2005). Rapid
shifts in the timing of the light–dark cycle, one of the most
powerful circadian synchronizers or so-called “Zeitgebers”,
lead to circadian desynchronization described in jet travelers
crossing more than two time zones, in shift workers and in
animal models (Arendt and Marks, 1982; Knutsson, 2003;
Nagano et al., 2003). Re-synchronization after a shift needs
a considerable amount of time, different for various functions
and rhythms (Yamazaki et al., 2000; Lemmer et al., 2002).
Exogenous melatonin accelerates re-synchronization and
therefore ameliorates symptoms of jet lag syndrome both in
humans and animals (Illnerová et al., 1989; Golombek and
Cardinali, 1993; Sharkey and Eastman, 2002).
The consequences of internal desynchronization in WAG/
Rij rats, a well-known, validated, genetic animal model of
childhood absence epilepsy (Depaulis and van Luijtelaar,
2006), have been previously described (Smyk et al., 2011,
2012). The occurrence of absence seizures in this strain of
rats, marked by the presence of short-lasting, bilateral and
synchronous 7–11 Hz spike–wave discharges (SWDs) in
the electroencephalogram (EEG), is organized in a 24 h
rhythm (van Luijtelaar and Coenen, 1988). In a constant
dim light condition and after an 8 h light phase delay, the
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rhythm of SWDs was found to desynchronize from the rhythm
of motor activity (Smyk et al., 2011, 2012). Opposite to the
gradual and stable re-synchronization of the motor activity
to the shifted photoperiod that was completed after 6 days,
re-synchronization of the rhythm of SWDs took longer and
developed in an irregular way. Moreover, the lack of internal
synchrony of rhythms was associated with an enhancement
of epileptic activity (Smyk et al., 2011, 2012). Considering a
close relationship between the occurrence of absence sei-
zures and sleep–wake states (Drinkenburg et al., 1991), we
aimed to determine to which of the sleep–wake state
rhythms, if any, SWDs are coupled during the re-
synchronization process.
A second goal of the present study was to investigate the
putative effects of sub-chronic administration of several
doses of agomelatine on the course of re-synchronization of
the rhythms of SWDs and sleep–wake states to an 8 h phase
delay. Agomelatine, a newly introduced antidepressant with
chronobiotic properties, is a potent agonist of melatonin
receptors subtypes 1 and 2 (MT1, MT2) and a weak antago-
nist of the serotonin receptor subtype 2 (5-HT2C) (de
Bodinat et al., 2010). The antidepressant action of agomela-
tine has been demonstrated in animal studies and in clinical
trials (Papp et al., 2003; Goodwin et al., 2009). Chronobiotic
properties of the drug have been reported in rats kept in con-
stant darkness (Martinet et al., 1996), in an 8 h phase
advance paradigm resembling jet-lag (Redman et al.,
1995), and in aged rodents (Koster-van Hoffen et al., 1993).
Melatonin and agomelatine are known to affect epileptic
activity in diverse seizure and epilepsy models such as pen-
tylenetetrazole, pilocarpine, kainite, quinolinate, glutamate
and NMDA models in mice (Lapin et al., 1998; Yildirim and
Marangoz, 2006; Aguiar et al., 2012; Dastgheib and Moezi,
2014), as well as penicillin-induced and absence seizures in
rats (Aygun et al., 2015; Ethemoglu et al., 2019). Although
ineffective against epileptogenesis induced in the kainic
acid-induced status epilepticus model, agomelatine given
chronically prevents neuronal damage and comorbid depres-
sion in rats (Thekalarova et al., 2017 and 2018). Melatonin
and agomelatine may also alter sleep–wake architecture in
the rat (Descamps et al., 2009). Considering the potential
hypnotic and antiepileptic effect of agomelatine, our sub-
chronic experiment was preceded by an acute study, which
enabled us to disentangle the putative effects of agomelatine
on sleep and epilepsy from the effects of the light phase
delay on re-synchronization. In the acute experiment the
effects of a single administration of several doses of agome-
latine on the number and mean duration of SWDs, on sleep–
wake states and circadian parameters of their rhythms were
investigated.
EXPERIMENTAL PROCEDURES
Animals
Thirty-two male, eight-months old WAG/Rij rats (Harlan, the
Netherlands), average weight 315 g ± 12 g at time of sur-
gery, were used. All protocols have been carried out in accor-
dance with guidelines of the Association for Assessment and
Accreditation of Laboratory Animal Care International (AAA-
LAC), and of the European Communities Council Directive
of 24 November 1986 (86/609/EEC) and were approved by
the Janssen Pharmaceutica Ethical Committee. Every effort
was made to minimize animal use and disturbances in animal
well-being.
Rats were singly-housed in individually ventilated Plexiglas
cages (25 × 22 × 18 cm) in a sound-attenuated room and
controlled environmental conditions throughout the experi-
ment as well as during the recovery period after surgery.
Environmental parameters were as follows: temperature:
22 ± 2 C; humidity: 60%; 12:12 light–dark cycle, light inten-
sity: ≈ 100 lx, (i.e. at the height of the recording box, while a
recessed lighting consoles managed diffuse and uniform light
levels below 60 lx within cages, a software-controlled dimmer
handled a gradual transition between light and dark cycles).
Standard laboratory chow (SAFE A04, Augy, France) and
tap water were available ad libitum.
All experiments were performed in a large scale EEG
laboratory setting under controlled conditions, in which ani-
mals were kept in their home cage and placed in individually
ventilated recording boxes 24 h before the start of the ﬁrst
baseline recording and throughout the sub-chronic experi-
ments in order to avoid any stress that may result from cage
changes and displacement of home-cages from the holding
room to recording room and vice-versa.
Rats were euthanized at the end of the study by a conven-
tional rodent CO2 euthanasia procedure.
Surgery
Surgery was performed using the protocol described earlier
(Ahnaou et al., 2009). Rats, under isoﬂurane anesthesia, were
equipped with electrodes for EEG and EMG recordings. A mix-
ture of 30% O2, 70% N2O and 5% isoﬂurane was adminis-
tered to animals as an initial induction for 2 min. Then, the
animals were mounted in a stereotaxic apparatus and were
given a continuous constant mixture of O2, N2O and 2% iso-
ﬂurane. The analgesic Piritramide (Dipidolor; Janssen Phar-
maceutica NV, Belgium) was administered before the
incision over the total length of the head. The oval area of
the scalp was removed, and the uncovered skull was cleared
of the periosteum in order to place 7 stainless steel ﬁxing screws
(diameter 1 mm), inserted bilaterally in the left and right hemi-
sphere along the antero-posterior axes in the following coor-
dinates: AP +2 mm, L +/−2 mm; AP −2 mm, L +/−2 mm and
AP −6.6 mm, L +/−2 mm from Bregma; and referenced to
the same ground electrode place midline above of the cere-
bellum. The incisor bar was −5 mm under the center of the
ear bar, according to the stereotactic atlas of Paxinos and
Watson (Paxinos and Watson, 2013). In addition, stainless
steel wire electrodes were placed in the muscles of the neck
to record EMG activity. Electrodes (stainless steel wire,
7N51465T5TLT, 51/46 Teﬂon Bilaney, Germany) were con-
nected to a pin (Future Electronics: 0672-2-15-15-30-27-10-
0) with a small insert (track pins; Dataﬂex: TRP-1558-0000)
and were ﬁt into a 10-holes connector after which the whole
assembly was ﬁxed to the cranium with dental cement. Rats
were allowed to recover for at least 10 days. Welfare of each
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animal was monitored by an animal inventory system with
regular observations of behavior and physical health.
EEG and EMG recordings
During the adaptation period and recordings, animals were
carefully connected via a rotating swivel allowing free move-
ment during recording procedures. Continuous EEG and
EMG signals were acquired at 2 kHz sample rate with an
input range of +/−500 mV through a Biosemi ActiveTwo sys-
tem (Biosemi, Amsterdam, the Netherlands) referenced to
the CMS-DRL ground (common mode reference for online
data acquisition and impedance measures, which is a feed-
back loop driving the average potential across the montage
close to the ampliﬁer zero). The signals were ampliﬁed, ana-
logue band-pass ﬁltered between 1 and 100 Hz and digitized
with 24-bit resolution. Steel wire electrodes were placed in
the muscles of the neck to record EMG activity. These proce-
dures and instrumentation have shown to be reliable for long-
term, high-quality EEG and sleep–wake organization analy-
sis (Ahnaou et al., 2015).
Pharmacological treatment
Saline, agomelatine (Sigma-Aldrich, Belgium) in doses of 2.5,
5 and 10 mg/kg dissolved in 20% cyclodextrin (Sigma-
Aldrich, Belgium) and 20% cyclodextrin alone for vehicle con-
trol condition were always administrated orally (in <10 ml/kg
volume) at 1 h before the onset of the dark period.
Experimental design
The acute study consisted of three experimental days. Each
day consisted of 24 h of simultaneous and continuous EEG
and EMG recordings. Recordings started at the last hour of
the light phase during which administrations took place, next
they were continued by 12 h during the dark phase and 11 h
during the light phase (light–dark switch via dusk-dawn tran-
sition of 10 min). Animals were randomly assigned to 4 con-
ditions: vehicle, 2.5, 5 and 10 mg/kg group of agomelatine
(n = 8 rats each condition). On the ﬁrst, baseline day, all rats
received saline as a within-subject control for and adaptation
to the administration procedure. On the second day, the treat-
ment day, animals received agomelatine or vehicle (control
condition). On the third, post-treatment day, oral administra-
tion of a compound was mimicked by picking up animals from
their cages without usage of the gavage tubes and pharma-
ceutical agents.
Next, the sub-chronic study consisted of 11 experimental
days and one period of extended darkness. Recording sche-
dule was the same as in the acute study design. Again, rats
were randomly assigned to 4 experimental groups (n = 8 rats
each): vehicle, 2.5, 5 and 10 mg/kg of agomelatine. On the
ﬁrst baseline day, all animals received saline 1 h before the
start of the dark phase. After that day, an 8 h phase shift in
the light–dark cycle was introduced by extending the subse-
quent dark period from 12 to 20 h. Recordings were contin-
ued for 10 consecutive, post-shift days. Every day, 1 h
before the dark phase, animals were given either agomela-
tine or vehicle (control group). Due to an unexpected
recording system failure, the data of the second post-shift
day were lost and are treated as ‘missing data’ in the analy-
sis. Experimental design is presented in Fig. 1.
The acute and sub-chronic study were separated by a two-
week washout period.
Data analysis
Five sleep–wake states were automatically identiﬁed for each
2 s epochs: active wakefulness, passive wakefulness, light
and deep slow-wave sleep and rapid-eye-movement sleep
(REM), based on EEG, EMG and body movements (PIR
detection) following validated criteria (Ahnaou and
Drinkenburg, 2011).
The number and duration of SWDs was scored automati-
cally based on the EEG signal from a frontal electrode
against reference according to validated criteria, next SWDs
were visually scored based on criteria published elsewhere
(Ovchinnikov et al., 2010).
Data from 24 h days of both acute and sub-chronic experi-
ment: duration of the ﬁve sleep–wake states (expressed in
min.), number and mean duration of SWDs (duration
expressed in sec.) were grouped into 1 h bins. Each hour of
the baseline day was compared with the corresponding hours
of the treatment and post-treatment days in the acute, and 10
post-shift days in the sub-chronic study, respectively.
The acrophases of active wakefulness, both slow-wave
sleep stages and SWDs rhythms, were based on 6 min bin
data, as previously described (Smyk et al., 2011, 2012).
Cosine wave of a ﬁxed 24 h period length was ﬁtted to each
of the 3 days of the acute study, baseline and all post-shift
days of the sub-chronic study (program Cosinor available at
http://www.circadian.org/softwar.html). Considering that the
shape of the passive wakefulness and REM sleep rhythms
during re-synchronization diverged signiﬁcantly from cosine
wave, their acrophases were assessed as follows: a position
of a peak for each day was determined visually based on
0.5 h bin data. Additionally, the timing of minima of those
rhythms was assessed as well. Also time series consisting
of all experimental days for all sleep–wake states and SWDs
(bin size: 6 min) were constructed and correlated with each
other to reveal the strength of the mutual relationships.
Statistical analysis
Statistical analyses were done in Statistica (StatSoft, Inc.,
Tulsa, OK, USA). Repeated measures analysis of variance
(ANOVA) were used to estimate dose, hour and day effect
of agomelatine treatment, on total duration of the ﬁve
sleep–wake states, mean duration and number of SWDs in
the acute study. The same variables were also determined
in the sub-chronic experiment in which, dose, phase (light
and dark) and day effects were investigated. Repeated mea-
sures ANOVA were also used to estimate the dose and day
effect of agomelatine treatment on circadian parameters of
the rhythms of sleep–wake states and SWDs in both studies.
Bonferroni's test was used as post-hoc test. The signiﬁcant F
values and their df are reported, followed by P values of the
post-hoc tests. Alternatively, Friedman ANOVA followed by
Dunn's multiple comparison test was used when the criterion
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of the normality of the data was not fulﬁlled. Pearson's corre-
lation coefﬁcients (r) were calculated to compare strength of
relationships between various rhythms throughout the sub-
chronic experiment. Differences were considered to be signif-
icant at P < .05.
RESULTS
Acute study
No dose effect of agomelatine or interactions of agomelatine
with days or hours were found on any variable investigated,
neither in the duration of sleep–wake states, number and
mean duration of SWDs or in any circadian parameters. Only
hour, day, and hour × day effects were found. However, the
magnitude of changes was small (in a range of 0.33–
0.70 min per 24 h in case of the duration of sleep–wake
states and 6.90–21 degrees per 360 degrees in case of the
acrophase, on the treatment versus baseline day). An ‘hour
× day’ interaction effect was found for the number of SWDs
(FHOUR × DAY = 8.18, all df = 46, 1288); post-hoc tests (all
P < .05) showed that the number of SWDs was decreased
for four consecutive hours (4th, 6th–8th) on the treatment
day compared to baseline and post-treatment day (Fig. 2).
Sub-chronic study
Dose effect or interactions of dose of agomelatine were not
found during the process of re-synchronization on any vari-
able investigated.
As a consequence of the phase shift, the total duration of
active wakefulness was reduced on 1st, 3rd and 4th day after
the shift (FDAY = 10.28, df = 9, 504, all P < .05). Active wake-
fulness was decreased in the dark phase from 1st to 7th post-
shift day, and increased in the light period (FDAY × PHASE =
243.24, df = 9, 504, all P < .05). Data are presented in Fig. 3.
During most post-shift days the total duration of passive
wakefulness was elevated across days (FDAY = 6.63, df =
9504, all P < .05). A robust increase was observed in the
light phase from 1st to 4th, 5th and 7th post-shift day, while
a nocturnal level was decreased on the 1st and 3rd post-
shift day and increased during the last 3 days of the experi-
ment (FDAY × PHASE = 54.51 df = 9504, all P < .05) (Fig. 3).
Changes of the total time spent in light slow-wave sleep
in the light and the dark phase across days were signiﬁcant
(FDAY = 3.18, df = 9, 504, P < .05), although they seemed
less pronounced in comparison to active and passive wake-
fulness. Both diurnal and nocturnal level of light slow-wave
sleep was increased and reduced, respectively only for
Fig. 1. Experimental design. EEG, EMG and activity were simultaneously recorded in symptomatic WAG/Rij rats injected with the melatonergic antidepres-
sant agomelatine (A) in an acute (B) and sub-chronic experiment (C).
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2 days after the phase shift (FDAY × PHASE = 12.66, df = 9,
504, all P < .05) (Fig. 3).
Total duration of deep slow-wave sleep was signiﬁcantly
elevated in the dark phase during the ﬁrst 5 days after the
phase-shift, while its duration in the light phase was
decreased for 4 days (FDAY × PHASE = 472.70, df = 9504, all
P < .05). On the ﬁrst post-shift day, typical phase-related dif-
ferences were noticed: the prolonged duration of deep slow-
wave sleep during the dark was compensated by a ﬁrm
reduction during the light phase (P < .05). (Fig. 3).
The duration of REM sleep was increased starting from the
1st to 6th post-shift day (FDAY = 12.71, df = 9504, all
Fig. 2. Duration (minutes) of sleep-wake states (mean ± SEM, n = 32) and occurrence (number) of SWDs (mean ± SEM, n = 32) across 24 h during saline
(A), treatment with various doses of agomelatine (B), and post-treatment day (C). Comparison between experimental days of the acute study (D). Data reso-
lution: 1 h. The dark phase of the 12:12 light–dark cycle is marked by gray rectangles. *P < .05, baseline vs treatment day, #P < .05, baseline vs post-treat-
ment day, ANOVA for repeated measures, Bonferroni post-hoc test.
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P < .05). This increase is completely due to the elevated
level of REM sleep in the dark phase (FDAY × PHASE = 28.87
df = 9504, P < .05) (Fig. 3).
Rats had more SWDs in the light phase of the ﬁrst 3 post-
shift days in comparison to baseline, while during the dark
phase of the same post-shift days SWDs were less numer-
ous (FDAY × PHASE = 21.04, df = 9, 36, all P < .05). The mean
duration of SWDs was increased on 3rd and 4th post-shift
days (FDAY = 3.87, df = 9, 36, all P < .05), the increase in
the light phase was present during the ﬁrst 3 post-shift days
(FDAY × PHASE = 3.28, df = 9, 36, all P < .05) as the main con-
tributor to this effect (Fig. 3). There were no dose effects or
interactions with dose of agomelatine on number and mean
duration of SWDs.
Circadian rhythmicity was detected in all sleep–wake
states and the occurrence of SWDs on the baseline day.
In general, dose effect of agomelatine and its interactions
were not found in acrophases of any of the rhythms investigated.
To avoid that the outcomes of circadian analyseswere overpow-
ered by the large number of animals (n = 32), only the data
from the control group (n = 8) were used to illustrate the pro-
cess of re-entrainment of various rhythms to the phase shift.
The position of acrophase changed over days in all
states and SWDs: active wakefulness: FDAY = 118.44, pas-
sive wakefulness: FDAY = 19.62, light slow-wave sleep: F-
DAY = 67.88, deep slow-wave sleep: FDAY = 99.06, REM
sleep: FDAY = 23.91, number of SWDs: FDAY = 10.08, all df =
9, 63, all P < .05. Immediately after the phase shift all acro-
phases were advanced of 43.00–151.87 degrees, except the
acrophase of the passive wakefulness. Phase-shift magni-
tude (the difference between the position of acrophase
between the baseline and the 1st phase-shift day) was differ-
ent for the different sleep–wake states (one-way ANOVA,
F = 23.50, df = 4, 35; P < .05). The acrophase of REM sleep
was affected the most, however, it accomplished the largest
daily shifts and was the fastest to re-synchronize (4th post-
shift day). Light slow-wave sleep and SWDs reached the
baseline values on the 7th day after the shift. Active wakeful-
ness and deep slow-wave sleep returned to the baseline on
the 8th post-shift day. An overview of the re-synchronization
is presented in Fig. 4.
During the re-synchronization process, circadian rhythmicity in
active wakefulness and both slow-wave sleep stages, deter-
mined by a signiﬁcant ﬁt of a cosine to the data, was present in
all animals, during all experimental days after the phase-shift.
However, a cosine was less well ﬁtted for the number of SWDs,
passivewakefulness, andREMsleepand this demonstrates that
these rhythms showed a poorer temporal organization. These
two latter states showed the greatest abnormalities during the
course of re-synchronization, even on the 10th post-shift day,
the expression of passive wakefulness and REM sleep in some
rats was not rhythmic as yet. On the ﬁrst post-shift day a large
peakof theREMsleepemergedduring the dark phase changing
the shape of the rhythm into bimodal. The peak persisted till 8th
post-shift day, as judged by a visual inspection of a double-
plotted actogram (Fig. 5). Contrary to the REM peaks, the
light–dark transition-related minimum did not change its posi-
tion during re-synchronization (Friedman ANOVA, F = 21.82,
df = 9, P < .05, Dunn's post-hoc test, baseline vs post-shift
days, all P > .05). Considering passive wakefulness, signiﬁ-
cant difference in maximal peak position was seen only on
the 4th post-shift day (Friedman ANOVA, F = 19.62, df = 9,
P < .05, Dunn's post-hoc test baseline vs post-shift days,
P < .05), while the minimum of the rhythm, typically located
at the transition between the dark and light phases, was sig-
niﬁcantly advanced into the dark phase for 4 post-shift days
(Friedman ANOVA, F = 39.16, df = 9, P < .05, Dunn's post-
hoc test, baseline vs post-shift days, all P < .05).
To verify whether particular rhythms were related to each
other, time series of their duration for all experimental days
were created (resolution: 6 min) and correlated with one
another. The strength of the relationship given by an absolute
value of Pearson's correlation coefﬁcient (r) was compared
by means of one-way ANOVA and was found signiﬁcantly dif-
ferent between various pairs of rhythms (F = 129,35, df = 14,
P < .05). The strongest relationship was seen for active-
wakefulness–deep slow-wave sleep and active wakeful-
ness–light slow-wave sleep pairs (r = 0.76 ± 0.01 and
0.69 ± 0.01, respectively, all P < .05, active-wakefulness–
deep slow-wave sleep and active wakefulness–light slow-
wave sleep vs the other pairs). The second was found for
passive wakefulness and deep slow-wave sleep (0.56 ±
0.01, all P < .05, passive wakefulness–deep slow-wave
sleep relationship vs others investigated) The third were
light–deep slow-wave sleep and active wakefulness–REM
sleep pairs (0.42 ± 0.01 and 0.37 ± 0.01, respectively; all
P < .05, light–deep slow-wave sleep, active wakefulness–
REM sleep pairs vs the remaining ones). The weakest rela-
tionships were found between REM sleep and the other
sleep–wake states with an exception of active wakefulness
(REM sleep–passive wakefulness: r = 0.16 ± 0.03; REM
sleep–light slow-wave sleep: r = 0.07 ± 0.02; REM sleep–
deep slow-wave sleep: r = 0.10 ± 0.01; REM sleep–SWDs:
r = 0.07 ± 0.01). SWDs were correlated the most with deep
slow-wave sleep (r = 0.25 ± 0.02), however the strength of
the mutual relationship did not differ signiﬁcantly from those
with active wakefulness and light slow-wave sleep (r =
0.21 ± 0.02, 0.16 ± 0.02, respectively, all P > .05). Data are
presented in Fig. 6.
DISCUSSION
Re-synchronization of various sleep–wake states and
absence seizures to an 8 h light phase delay was investi-
gated in a validated animal model of childhood absence
Fig. 3. Total daily duration (minutes) of sleep–wake states (mean ± SEM, n = 8), occurrence (number) and mean duration (seconds) of SWDs (mean ± SEM,
n = 8) during baseline and post-shift days (A). Total duration of several sleep–wake states (mean ± SEM, n = 8), occurrence (number) and mean duration
(seconds) of SWDs (mean ± SEM, n = 8) in the light and the dark phase of the photoperiod during baseline and post-shift days (B). *P < .05, baseline vs
post-shift day, ANOVA for repeated measures, Bonferroni post-hoc test.
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epilepsy, rats of the WAG/Rij strain. The present study ﬁrstly
aimed to determine the time dynamics of the process and a
putative relationship between vigilance rhythms and the
rhythm of SWDs. Secondly, the effects of agomelatine were
evaluated with respect to duration of sleep–wake states and
number of SWDs during stable entrainment (acute study)
and after the phase shift (sub-chronic study). Different
speeds of re-synchronization of sleep–wake states and
Fig. 4. Re-entrainment of sleep–wake states (mean ± SEM, n = 8) and SWDs (mean ± SEM, n = 8) after an 8 h light phase delay. Total duration of sleep–
wake states in minutes and the number of SWDs during particular post-shift days were plotted with respect to the baseline. The dark phase of the 12:12 light–
dark cycle is marked by gray rectangles. *P < .05, acrophase of the baseline vs acrophase on the post-shift day, #P < .05, nadir of the baseline vs nadir of the
post-shift day, ANOVA for repeated measures, Bonferroni post-hoc test or Friedman ANOVA, Dunn's multiple comparison post-hoc test.
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SWDs rhythms, correlations between various rhythms, and a
lack of effect of agomelatine both in the acute and sub-
chronic administration comprise the main ﬁndings.
Desynchronization between different sleep–wake states
after a phase shift has been described previously in rats
(Sei et al., 1992, 1994). Striking was the increase in REM
sleep duration during the dark phase. Considering shift mag-
nitude and time differences in reaching baseline values, the
acrophase of REM sleep was shifted the most, however, it
re-synchronized as ﬁrst. Although REM sleep propensity is
well known to be controlled by the circadian timing system
and inversely coupled to the body temperature rhythm in
Fig. 5. Double-plotted actograms of the duration (minutes) of the different sleep–wake states (mean ± SEM, n = 8) and the number of SWDs (mean ± SEM,
n = 8) across all experimental days. Each row represents 2 consecutive days of the experiment (48 h). The second day (24 h) in each row is then plotted
again as the ﬁrst day in the row below as marked by the thin arrows on active wakefulness actogram. The beginning of the shifted photoperiod (the ﬁrst
post-shift day) is marked by thick arrows. The dark phase of the 12:12 light–dark cycle is marked by gray rectangles. *P < .05, acrophase of the baseline
vs acrophase on the post-shift day, #P < .05, nadir of the baseline vs nadir of the post-shift day, ANOVA for repeated measures, Bonferroni post-hoc test
or Friedman ANOVA, Dunn's multiple comparison post hoc test.
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humans (Czeisler et al., 1980) and rats (Cambras et al.,
2007), the amplitude of the REM sleep rhythm is small in
comparison to active wakefulness or slow-wave sleep
(Borbély et al., 1975). Rhythms with small circadian ampli-
tude accomplish larger shifts and their rate of re-
synchronization is faster (Reinberg et al., 1978). In agree-
ment with this theory, the rhythms of light slow-wave sleep
and SWDs, both with average amplitude, completed the shift
three days after REM sleep, while active wakefulness and
deep slow-wave sleep, both have a large circadian ampli-
tude, were the slowest to re-synchronize. However, it should
be mentioned that although the acrophase of the REM sleep
re-synchronized ﬁrstly, the increase in its daily amount, espe-
cially during the dark phase, was the most prolonged. Similar
changes regarding duration of REM sleep were observed in
mice subjected to chronic environmental circadian disruption
(Brager et al., 2013).
Internal desynchronization is thought to be a consequence
of desynchrony between anatomically and functionally dis-
tinct subregions of the suprachiasmatic nucleus (SCN). Cir-
cadian regulation of sleep, slow-wave sleep and locomotor
activity was associated with the activity of both the ventrolat-
eral and dorsomedial SCN, while circadian regulation of REM
sleep depended merely on the activity of the dorsomedial
SCN (Cambras et al., 2007; Lee et al., 2009). In the present
study, the strongest relationship across all experimental days
was seen between active wakefulness and both stages of
slow-wave sleep, it was signiﬁcantly stronger than active
wakefulness–REM sleep relationship. Moreover, REM sleep
showed the weakest correlations with the remaining sleep–
wake states and SWDs. Based on this ﬁnding, together with
same re-synchronization rate, we hypothesize that active
wakefulness and deep slow-wave sleep are governed by
the same circadian mechanism distinct from REM sleep.
Considering the speed of re-synchronization, the rhythm of
SWDs and light slow-wave sleep re-entrained together which
may suggest that both rhythms are controlled by a common
mechanism.
The phase shift affected the timing of epileptic activity:
while the total number of SWDs remained unchanged, a
light–dark redistribution occurred. After the shift, SWDs were
more prevalent during the light and less prevalent during the
dark period. The elevation during the light was accompanied
by an increase in the total duration of passive wakefulness
and a marked reduction of deep slow-wave sleep. Consider-
ing the tight relationship between SWDs and vigilance
(Drinkenburg et al., 1991), it seems that the balance between
SWDs enhancing and inhibiting brain states is shifted
towards favorable conditions for SWDs to occur. Similar
results were obtained in our earlier study, in which WAG/Rij
rats were exposed to the same light–dark manipulation, how-
ever, without pharmacological intervention and without an
explanation in terms of sleep–wake states (Smyk et al.,
2012).
Neither dose-dependent nor drug effects of agomelatine on
sleep–wake states and SWDs were found in the acute study.
However, an ‘hour × day’ interaction was noticed for the num-
ber of SWDs; they were decreased for four consecutive
hours during the treatment day. It cannot be excluded that
Cyclodextrin (20%) used as a vehicle and given only on treat-
ment day accounted for the effect observed. Cyclodextrins
are cyclic oligosaccharides containing 6–8 glucose units con-
nected by α-(1, 4) bonds. This particular formation (hydrophi-
lic outside, hydrophobic inside) accounts for their ability to
create inclusion compounds with other hydrophobic mole-
cules increasing their stability, solubility and bioavailability
and are widely used (Duchene et al., 1986; Davis and Brew-
ster, 2004). Considered as neutral solvent, cyclodextrins
were reported to exert neuroactive effect both in vitro and in
vivo (Wang et al., 2003; Shu et al., 2004; Pytel et al., 2006).
In WAG/Rij rats, hippocampal microinjections of cyclodextrin
(45% solution) had a biological relevant effect (it reduced the
number of SWDs to 1 h after the administration)
(Tolmacheva and van Luijtelaar, 2007). In the present study,
the number of SWDs was decreased during the treatment
day between 4 and 8 h after administration. Differences in
time, during which the effect was manifested may be attribu-
ted either to the route of administration: local vs systemic or,
considering a slight passage of cyclodextrin through blood–
brain barrier (Monnaert et al., 2004), behavioral effects of
the administration such as arousal, stomach load, increased
thirst may be responsible for the effect observed. Also, in
the sub-chronic study the daily oral administration of agome-
latine did not affect any of the characteristics of the rhythms
investigated, nor the speed of the re-synchronization after
the phase shift. Given the chronobiological character of the
study, dosage of the compound for both experiments
Fig. 6. The strength of the mutual relationships (the absolute value of
Pearson's correlation coefﬁcient (r)) between various pairs of sleep–wake
states and SWDs. *P < .05, one-way ANOVA, Bonferroni post-hoc test.
Numbers above each data bar represents signiﬁcant difference between
that pair of sleep–wake states and the other pair coded by this particular
number. AW = active wakefulness, PW = passive wakefulness, SWS
L = light slow-wave sleep, SWS D = deep slow-wave sleep, REM =
REM sleep, SWDs = spike–wave discharges.
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(between 2.5–10 mg/kg), was based on its ability to synchro-
nize circadian rhythms, as it was shown previously that an
oral dose of 5.7 mg/kg provided true entrainment (Martinet
et al., 1996). Moreover, the highest dose used in the present
study (10 mg/kg) was found to induce changes in sleep–
wake architecture in a period between 4 and 7 h after the
administration and also during the following day (Descamps
et al., 2009). The reasons behind the lack of the agomelatine
effectiveness observed in the present study might be as fol-
low: both experiments of the present study were conducted
in 12:12 light–dark cycle in contrast to constant darkness as
in Martinet et al. (1996), therefore, it cannot be excluded that
the presence of this powerful Zeitgeber outweighed the
effects of the compound. Furthermore, the transient arousal
(Hastings et al., 1992) produced by oral administration of
the drug might have masked its effect on the rhythms. On
the other hand, our results are in accordance with other stu-
dies concluding that agomelatine, when given shortly before
the dark onset, failed to affect sleep–wake states in nocturnal
rodents (Tobler et al., 1994).
To conclude, the present study demonstrates internal
desynchronization between various sleep–wake states and
SWDs after a rapid shift in the timing of the light phase of
the photoperiod. The SWDs rhythm re-entrained together
with light slow-wave sleep, a state frequently preceding the
occurrence of absence seizures. This suggests a common
mechanism for their co-occurrence, distinct from the one gov-
erning activity and deep slow-wave sleep. Circadian misa-
lignment caused by the phase shift resulted in an
aggravation of epileptic activity in the light phase, during
which SWDs in WAG/Rij rats are more sparse than in the
dark phase. An increased duration of passive wakefulness
seems to be responsible for the increase, since, this sleep–
wake state acts as SWDs enhancer. Treatment with the mel-
atonin agonist was found ineffective in the acute sleep–wake
study, as well in the phase delay paradigm. It also lacked
effect on epileptic activity. The redistribution of the sleep–
wake states across the 24 h during the re-entrainment pro-
cess might be of signiﬁcant importance for epilepsy patients,
who are planning trans meridian ﬂights across time zones
and are dealing with adverse consequences of jet lag.
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